A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Enith2
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes
2 other identifiers
interventional
1,600
19 countries
163
Brief Summary
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Mar 2026
163 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 16, 2026
CompletedFirst Posted
Study publicly available on registry
January 20, 2026
CompletedStudy Start
First participant enrolled
March 23, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 7, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 7, 2028
July 20, 2026
July 1, 2026
2.4 years
January 16, 2026
July 17, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Percent (%) Change from Baseline in Body Weight at Week 72
Baseline through Week 72
Secondary Outcomes (40)
Percentage of Participants Achieving ≥5% Body Weight Loss from Baseline at Week 72
Baseline and Week 72
Percentage of Participants Achieving ≥10% Body Weight Loss from Baseline at Week 72
Baseline and Week 72
Percentage of Participants Achieving ≥15% Body Weight Loss from Baseline at Week 72
Baseline and Week 72
Change from Baseline in Body Weight (kg) at Week 72
Baseline through Week 72
Change from Baseline in Hemoglobin A1c (HbA1c) at Week 72
Baseline through Week 72
- +35 more secondary outcomes
Study Arms (4)
Arm 1: Placebo
PLACEBO COMPARATORArm 2: Enicepatide Dosing Regimen 1
EXPERIMENTALArm 3: Enicepatide Dosing Regimen 2
EXPERIMENTALArm 4: Enicepatide Dosing Regimen 3
EXPERIMENTALInterventions
Placebo will be volume-matched and administered once weekly using an integrated drug-device combination product.
Enicepatide will be administered once weekly at the randomized dosing regimen using an integrated drug-device combination product.
Eligibility Criteria
You may qualify if:
- Ability and willingness to self-administer the study drug (or receive an injection from a trained individual if visually impaired or with physical limitations)
- Diagnosis of type 2 diabetes mellitus (T2DM) according to WHO classification or other locally applicable standards with HbA1c ≥6.5% to ≤10% determined by laboratory test at screening, and on stable oral therapy for at least 3 months prior to screening (if applicable). T2DM may be treated with diet/exercise alone or any oral anti-hyperglycemic medication (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1 RA-based therapy.
- Body mass index (BMI) ≥27.0 kg/m\^2
- History of ≥1 self-reported unsuccessful diet/exercise effort to lose body weight
You may not qualify if:
- History of type 1 diabetes mellitus (T1DM) or any lifetime history of ketoacidosis or history of hyperosmolar state/coma within 12 months prior to screening
- Have had 1 or more episodes of severe hypoglycemia and/or has hypoglycemia unawareness within the 6 months prior to screening
- At least 2 confirmed fasting blood glucose values \>270 mg/dL (15.0 mmol/L) (on 2 non-consecutive days) during screening
- Self-reported change in body weight \>5 kg within 3 months prior to screening
- Obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin 4 receptor deficiency or Prader-Willi syndrome)
- Prior or planned surgical treatment for obesity. Liposuction or abdominoplasty if performed more than 1 year prior to screening is allowed.
- Known clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction)
- Poorly controlled hypertension at screening
- Have any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)/transient ischemic attack; Unstable angina; Hospitalization due to congestive heart failure
- Treatment with any approved or investigational GLP-1-RA-based therapy (e.g., GLP-1 receptor mono agonist, GLP-1/GIP receptor dual agonist, GLP-1/GIP/Gluc receptor triple agonist) within 6 months prior to randomization
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (163)
Lakeview Clinical Research
Guntersville, Alabama, 35976, United States
Arizona Clinical Trials
Tucson, Arizona, 85711, United States
Orange County Research Center
Lake Forest, California, 92630, United States
Ark Clinical Research
Long Beach, California, 90815, United States
Catalina Research Institute, LLC
Montclair, California, 91763, United States
Infinity Clinical Research
Norco, California, 92860, United States
Prospective Research Innovations Inc.
Rancho Cucamonga, California, 91730, United States
Encompass Clinical Research
Spring Valley, California, 91978, United States
Emerson Clinical Research Institute
Washington D.C., District of Columbia, 20009, United States
Tampa Bay Medical Research, Inc.
Clearwater, Florida, 33761, United States
Center for Diabetes, Obesity and Metabolism Inc
Pembroke Pines, Florida, 33024, United States
Progressive Medical Research
Port Orange, Florida, 32127, United States
Eirvera, LLC
St. Petersburg, Florida, 33711, United States
Centricity Research Columbus Georgia Multispecialty
Columbus, Georgia, 31904, United States
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia, 30291, United States
Elevate Clinical Research
Lake Charles, Louisiana, 70605, United States
DelRicht Clinical Research, LLC
New Orleans, Louisiana, 70115, United States
Centennial Medical Group
Columbia, Maryland, 21045-5840, United States
Centricity Research Morehead City Multispeciality
Morehead City, North Carolina, 28557, United States
Remington Davis Inc
Columbus, Ohio, 43215, United States
Lynn Institute of Norman
Norman, Oklahoma, 73072, United States
Lynn Health Science Institute
Oklahoma City, Oklahoma, 73112, United States
Essential Medical Research
Tulsa, Oklahoma, 74137, United States
VA Pittsburgh Healthcare System
Pittsburgh, Pennsylvania, 15240, United States
Coastal Carolina Research Center
North Charleston, South Carolina, 29405, United States
Circle Clinical Research
Sioux Falls, South Dakota, 57104, United States
Velocity Clinical Research
Dallas, Texas, 75230, United States
South Texas Research Institute - Edinburg
Edinburg, Texas, 78539, United States
HRI ? Medical Center, LLC
Houston, Texas, 77004, United States
Juno Research, LLC
Houston, Texas, 77040, United States
HRI ? Pasadena, LLC
Pasadena, Texas, 77505, United States
DM Clinical Research
Tomball, Texas, 77375, United States
Manassas Clinical Research Center
Manassas, Virginia, 20110, United States
Centricity Research Suffolk Primary Care
Suffolk, Virginia, 23435, United States
Era Health Research
Redmond, Washington, 98052, United States
CINME
Buenos Aires, C1056ABI, Argentina
CEDIC Centro de Investigaciones Clinicas
Buenos Aires, C1060ABN, Argentina
Centro Medico Viamonte SRL
Buenos Aires, C1120AAC, Argentina
IME - Instituto Médico Especializado
Buenos Aires, C1405BCH, Argentina
Instituto centenario
Ciudad Autonoma Buenos Aires, C1204AAD, Argentina
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Ciudad Autonoma Buenos Aires, C1425AGC, Argentina
Centro de Investigaciones Medicas Mar Del Plata
Mar del Plata, B7600FYK, Argentina
Paratus Clinical Western Sydney
Blacktown, New South Wales, 2148, Australia
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
Logan Hospital
Meadowbrook, Queensland, 4131, Australia
Southern Adelaide Diabetes and Endocrine Services (SADES)
Oaklands Park, South Australia, 5046, Australia
Baker Heart and Diabetes Insitute
Melbourne, Victoria, 3004, Australia
Centricity Research Calgary Endocrinology
Calgary, Alberta, T2H 2G4, Canada
TGElliott Inc. dba BC Diabetes
Vancouver, British Columbia, V5Y 3W2, Canada
Centricity Research Brampton Endocrinology
Brampton, Ontario, L6S 0C6, Canada
Medicor Research Inc
Greater Sudbury, Ontario, P3C 1X3, Canada
LMC Clinical Research Inc
Toronto, Ontario, M4G 3E8, Canada
Diex Recherche Sherbrooke
Sherbrooke, Quebec, J1L 0H8, Canada
Clinique des maladies lipidiques de Quebec
Québec, G1V 4W2, Canada
Huai He Hospital of Henan University
Kaifeng, Henan, 475001, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, 221002, China
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, 212002, China
Yan'an University Xianyang Hospital
Xianyang, Shaanxi, 712000, China
Jinan Central Hospital
Jinan, Shandong, 250013, China
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, 315010, China
Peking University People's Hospital
Beijing, 100044, China
Beijing Pinggu Hospital
Beijing, 101200, China
The First Hospital of Jilin University
Changchun, 130021, China
The Second People's Hospital of Hefei
Hefei, 230011, China
Huizhou Central People's Hospital
Huizhou, 516001, China
Hebei Petro China Central Hospital
Langfang, 065000, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, DUMMY_VALUE, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, 210003, China
Affiliated Drum Tower Hospital of Nanjing University Medical School
Nanjing, 210008, China
Pingxiang People's Hospital
Pingxiang, 337000, China
Shanghai Pudong New Area People's Hospital
Shanghai, 201299, China
Shanghai Fifth People's Hospital Affiliated to Fudan University
Shanghai, 201304, China
The First Affiliated Hospital of Soochow University
Suzhou, 215333, China
Wuxi People's Hospital
Wuxi, 214023, China
DIACENTRUM Brandýs nad Labem s.r.o.
Brandýs nad Labem, 25001, Czechia
Diavital Jesenice s.r.o.
Jesenice, 25242, Czechia
FLEDIP s.r.o.
Prague, 160 00, Czechia
TreDia s.r.o.;Diabetologická ambulance Praha 9
Praha 9 - Klánovice, 19014, Czechia
Hopital Saint Joseph Saint Luc
Lyon, 69007, France
Hopital de la Conception
Marseille, 13000, France
CHU de Nice
Nice, 06602, France
European Hospital Georges Pompidou (HEGP)
Paris, 75908, France
Chu De Tours
Tours, 37000, France
Hector-Center für Ernährung, Bewegung und Sport, Universitätsklinikum Erlangen;Medizinische Klinik 1 ? Gastroenterologie, Pneumologie und Endokrinologie
Erlangen, 91054, Germany
InnoDiab Forschung GmbH
Essen, 45136, Germany
Medizentrum Essen Borbeck
Essen, 45355, Germany
Unterfrintroper Hausarztzentrum
Essen, 45359, Germany
Universitaets Klinikum Frankfurt - Zentrum der Inneren Medizin
Frankfurt, 60596, Germany
Diabeteszentrum Hamburg West
Hamburg, 22607, Germany
Mesut Durmaz - Facharzt für Innere Medizin, Endokrinologie & Diabetologie
Hof, 95030, Germany
Zentrum für klinische Forschung Köln - Dünnwald;Dünnwald Praxis
Köln - Dünnwald, 51069, Germany
Schwerpunktpraxis für Diabetes und Ernährungsmedizin, Dr. med. Winfried Keuthage
Münster, 48153, Germany
Diabetologische Schwerpunktpraxis Pirna Hausärztliche Versorgung
Pirna, 01796, Germany
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo, Abruzzo, 24127, Italy
Azienda Ospedaliero-Universitaria "Renato Dulbecco" Catanzaro
Catanzaro, Calabria, 88100, Italy
A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna
Bologna, Emilia-Romagna, 40138, Italy
Umberto I Policlinico di Roma-Università di Roma La Sapienza
Rome, Lazio, 00161, Italy
Policlinico Universitario Agostino Gemelli
Rome, Lazio, 00168, Italy
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Palermo, Sicily, 90127, Italy
AO di Perugia - Ospedale S. Maria della Misericordia
Perugia, Umbria, 06156, Italy
Kasugai Municipal Hospital
Aichi, 486-8510, Japan
Fukuhama Chuo Clinic
Fukuoka, 810-0066, Japan
NTT Medical Center Sapporo
Hokkaido, 060-0061, Japan
Hasegawa Medicine Clinic
Hokkaido, 066-0032, Japan
The University of Osaka Hospital
Osaka, 565-0871, Japan
Higashijujo Sakai Diabetes Internal Medicine Clinic
Tokyo, 114-0001, Japan
Arechavaleta Granell Maria del Rosario
Guadalajara, Jalisco, 44650, Mexico
Clinicos Asociados Bocm, S.C.
México, Mexico CITY (federal District), 03300, Mexico
Avant Santé Research Center
San Pedro Garza García, Nuevo León, 66260, Mexico
NZOZ Osteo-Medic s.c. A. Racewicz, J.Supronik
Bialystok, Podlaskie Voivodeship, 15-351, Poland
Centrum Medyczne INTERCOR Sp. z o.o.
Bydgoszcz, 85-605, Poland
ETG Debica
Dębica, 39-200, Poland
Ekamed sp. z o.o.
Lublin, 20-718, Poland
NZOZ Eskulap Pabianice
Pabianice, 95-200, Poland
Centrum Medyczne OMEDICA
Poznan, 60-111, Poland
NZOZ Przychodnia Specjalistyczna Andrzej Wittek, Henryk Rudzki s.c.
Ruda Śląska, 41-709, Poland
ETG Siedlce
Siedlce, 08-110, Poland
Panstwowy Instytut Medyczny - MSWiA
Warsaw, 02-507, Poland
NZOZ Regionalna Poradnia Diabetologiczna
Wroclaw, 50-127, Poland
FDI Clinical Research
San Juan, 00927, Puerto Rico
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggido, 13620, South Korea
Yonsei University Wonju Severance Christian Hospital
Gangwon-do, 26426, South Korea
Chosun University Hospital
Gwangju, 61453, South Korea
Eulji General Hospital
Seoul, 01830, South Korea
Kangbuk Samsung Hospital
Seoul, 03181, South Korea
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
Complejo Hospitalario Universitario A Coruña
A Coruña, LA Coruna, 15006, Spain
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Madrid, 28223, Spain
Centro Medico Teknon
Barcelona, 08022, Spain
Hospital Universitari Vall d Hebron
Barcelona, 08035, Spain
Hospital Gregorio Marañon
Madrid, 28007, Spain
Hospital Universitario Fundacion Jimenez Diaz.
Madrid, 28040, Spain
Hospital Universitario Virgen de la Victoria
Málaga, 29010, Spain
Nuevas Tecnologias en Diabetes y Endocrinologia
Seville, 41003, Spain
Changhua Christian Hospital
Changhua, 50006, Taiwan
Chia-Yi Christian Hospital
Chiayi City, 600, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 80756, Taiwan
Chung Shan Medical University Hospital
Taichung, 40201, Taiwan
China Medical University Hospital
Taichung, 40447, Taiwan
National Cheng Kung University Hospital
Tainan, 70403, Taiwan
National Taiwan University Hospital
Taipei, 10048, Taiwan
Taipei Veterans General Hospital
Taipei, 112, Taiwan
Rajavithi Hospital
Bangkok, 10400, Thailand
Ramathibodi Hospital
Bangkok, 10400, Thailand
Siriraj Hospital
Bangkok, 10700, Thailand
Division of Endocrinology and Metabolism;Internal Medicine
Chiang Mai, 50200, Thailand
Songklanagarind Hospital
Hat Yai, 90110, Thailand
Thammasat University Hospital
Khlong Luang, 12120, Thailand
Ankara University Medical Faculty
Ankara, 06100, Turkey (Türkiye)
Akdeniz University Medical Faculty
Antalya, 07059, Turkey (Türkiye)
Dokuz Eylul University Medicine Faculty
Izmir, 35340, Turkey (Türkiye)
Baskent Universitesi - Adana Uygulama Ve Arastirma Merkezi
Sariçam, 01250, Turkey (Türkiye)
Fylde Coast Clinical Research at Layton Medical Centre
Blackpool, Lancashire, FY3 7EN, United Kingdom
Aberdeen Royal Infirmary
Aberdeen, AB9 2ZB, United Kingdom
Antrim Area Hospital
Antrim, BT41 2RL, United Kingdom
Southmead General Hospital
Bristol, BS10 5NB, United Kingdom
Ninewells Hospital and Medical School - Tayside Health Board
Dundee, DD1 9SY, United Kingdom
Hull Royal Infirmary
Hull, HU3 2JZ, United Kingdom
HMC Health Group
London, TW47NR, United Kingdom
George Eliot Hospital
Nuneaton, CV10 7DJ, United Kingdom
Knowle House Surgery
Plymouth, PL5 3JB, United Kingdom
Musgrove Park Hospital
Taunton, TA1 5DA, United Kingdom
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Clinical Trials
Hoffmann-La Roche
Central Study Contacts
Reference Study ID Number: WC45726 https://forpatients.roche.com/ No attachments to email below.
CONTACT
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 16, 2026
First Posted
January 20, 2026
Study Start
March 23, 2026
Primary Completion (Estimated)
August 7, 2028
Study Completion (Estimated)
August 7, 2028
Last Updated
July 20, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will share
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing